Achievement of LDL-Cholesterol Goals in Patients Receiving LLT in Primary Care: TERESA-AP Study
Impacto
Scholar |
Otros documentos de la autoría: Cinza-Sanjurjo, Sergio; barrios, vivencio; Fierro González, David; Polo Garcia, Jose; Pallarés-Carratalá, Vicente
Metadatos
Mostrar el registro completo del ítemcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/36080
comunitat-uji-handle3:10234/36082
comunitat-uji-handle4:
INVESTIGACIONMetadatos
Título
Achievement of LDL-Cholesterol Goals in Patients Receiving LLT in Primary Care: TERESA-AP StudyAutoría
Fecha de publicación
2024-07-03Editor
Wiley Open AccessISSN
1755-5914; 1755-5922Cita bibliográfica
Cinza-Sanjurjo, Sergio, et al. "Achievement of LDL‐Cholesterol Goals in Patients Receiving LLT in Primary Care: TERESA‐AP Study: LDL‐Cholesterol Goals in Primary Care." Cardiovascular Therapeutics 2024.1 (2024): 4227941.Tipo de documento
info:eu-repo/semantics/articleVersión
info:eu-repo/semantics/publishedVersionPalabras clave / Materias
Resumen
Background and Aim: Since 2019, LDL-cholesterol (LDL-C) is the risk factor with the strictest goals and the most difficult to reach, due to its role in the development of atherosclerotic plaque and, therefore, cardi ... [+]
Background and Aim: Since 2019, LDL-cholesterol (LDL-C) is the risk factor with the strictest goals and the most difficult to reach, due to its role in the development of atherosclerotic plaque and, therefore, cardiovascular risk. The objective of the TERESA-AP study is to analyze the degree of LDL-C control in patients followed up in primary care with lipid-lowering drug treatment (LLT).
Methods: Observational, multicenter, cross-sectional, nationwide study was conducted, in which 50 PC physicians recruited 929 patients who were receiving LLT during at least the preceding 6 months. The variables required to estimate the patients’ cardiovascular risk and LDL control were recorded.
Results: Nearly half of sample was women (50.5%), and the mean age was 67.8 (10.4) years. High blood pressure (65.3%) and sedentary lifestyle (59.7%) were the most frequent risk factors. Recommended goals were reached in 26.0% (95% CI: 23.3%–29.0%) of patients, with a slightly higher percentage in patients with cardiovascular disease (CVD) (26.7%), diabetes mellitus (DM) (35.5%), and a lower one in patients with chronic kidney disease (CKD) (12.1%). The most frequent drug treatments were statin monotherapy (69.0%) and statin with ezetimibe combination (27.6%), with moderate-intensity statins being the most commonly used in both groups.
Conclusions: On average, only a quarter of the patients followed up in PC and who receive drug treatment reach their therapeutic targets. This percentage is slightly higher if the patients have CVD and DM and lower if they have CKD. The most commonly used therapeutic strategy is moderate-intensity statins, both in monotherapy and in combination with ezetimibe. [-]
Publicado en
WileyCardiovascular TherapeuticsVolume 2024, Article ID 4227941, 9 pageshttps://doi.org/10.1155/2024/4227941Datos relacionados
Data are contained in the article.Entidad financiadora
Fundacion SEMERGEN | unconditional grant from Almirall SA.
Derechos de acceso
info:eu-repo/semantics/openAccess
Aparece en las colecciones
- MED_Articles [669]
Excepto si se señala otra cosa, la licencia del ítem se describe como: Copyright © 2024 Sergio Cinza-Sanjurjo et al. This is an open access article distributed under the Creative Commons AttributionLicense, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work isproperly cited.